Cytonics CEO Joey Bose discussed their groundbreaking approach to osteoarthritis with investor Kevin O’Leary. The biotech firm has treated over 10,000 patients and developed a therapy, CYT-108, which has completed Phase 1 trials. With $15M raised from 6,000 everyday investors, Cytonics challenges traditional Big Pharma funding models.
